Kimelman & Baird LLC Acquires New Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Kimelman & Baird LLC bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 600 shares of the medical equipment provider’s stock, valued at approximately $65,000.

Several other institutional investors also recently bought and sold shares of ZBH. OLD Point Trust & Financial Services N A acquired a new position in shares of Zimmer Biomet during the 4th quarter valued at about $26,000. Ables Iannone Moore & Associates Inc. acquired a new position in Zimmer Biomet during the fourth quarter valued at approximately $30,000. Crewe Advisors LLC acquired a new position in Zimmer Biomet during the first quarter valued at approximately $31,000. Family Firm Inc. acquired a new stake in shares of Zimmer Biomet in the second quarter worth $33,000. Finally, J.Safra Asset Management Corp boosted its holdings in shares of Zimmer Biomet by 712.1% during the 1st quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 235 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. TD Cowen dropped their target price on shares of Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating on the stock in a report on Friday, September 6th. Royal Bank of Canada cut their price objective on Zimmer Biomet from $140.00 to $130.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Wolfe Research started coverage on Zimmer Biomet in a report on Tuesday, September 10th. They issued a “peer perform” rating on the stock. UBS Group cut their price target on Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating for the company in a report on Thursday, August 8th. Finally, Piper Sandler downgraded shares of Zimmer Biomet from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $140.00 to $115.00 in a research note on Monday, July 1st. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $125.17.

Get Our Latest Research Report on Zimmer Biomet

Zimmer Biomet Stock Down 0.2 %

Shares of ZBH opened at $107.96 on Tuesday. The company has a quick ratio of 0.63, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. The company has a 50-day moving average price of $109.60 and a two-hundred day moving average price of $114.56. The stock has a market cap of $22.21 billion, a price-to-earnings ratio of 23.37, a P/E/G ratio of 1.98 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 12 month low of $102.00 and a 12 month high of $133.90.

Zimmer Biomet (NYSE:ZBHGet Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 EPS for the quarter, beating the consensus estimate of $1.99 by $0.02. Zimmer Biomet had a return on equity of 12.86% and a net margin of 13.25%. The business had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.94 billion. During the same quarter in the previous year, the firm earned $1.82 EPS. Zimmer Biomet’s quarterly revenue was up 3.9% on a year-over-year basis. Equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.89%. The ex-dividend date of this dividend is Monday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 20.78%.

Zimmer Biomet Profile

(Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Featured Articles

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.